Read more

April 24, 2024
2 min watch
Save

VIDEO: Clinical trials show efficacy of Vevye for dry eye disease

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

BOSTON — In this Healio Video Perspective from the ASCRS meeting, Alice T. Epitropoulos, MD, FACS, discusses Vevye, a cyclosporine solution that treats signs and symptoms of dry eye disease.

Epitropoulos said Vevye (Harrow) is “the most potent cyclosporine commercially available at 0.1%,” but it is tolerable, comfortable and efficacious, adding that it has been shown to remain in the tears for up to 8 hours.

“Of the 1,100 subjects involved in the FDA clinical trials, 57% demonstrated an improvement in total corneal fluorescein staining at day 15, and 66% demonstrated an improvement at day 29,” Epitropoulos said. “Patients saw an average of 98% increase in tear production at 56 weeks.”